Tyler Perrin Bellelo, M.D.

02/25/2026

The trials are clear.
When treatment stops, weight often returns.

That’s physiology — not failure.

Dr. Tyler Perrin-Bellelo, MD, FACP, D-ABOM
Internal Medicine | Obesity Medicine

02/25/2026

If weight gain recurs after stopping GLP one therapy is it failure or is it biology? Our next series is in production.

02/24/2026

It’s monitored metabolic care.

Labs. Protein. Micronutrients. Follow-up.

That’s medicine.

Dr. Tyler Perrin-Bellelo, MD, FACP, D-ABOM
Internal Medicine | Obesity Medicine

02/24/2026

If you don’t meet medical criteria,
you don’t need medical therapy.

02/23/2026

NAD is not a p*pt*de.
NMN and NR aren’t either.
Different structure. Different mechanism. Different science.
Stop letting the wellness industry blur the lines.

— Tyler Perrin-Bellelo, MD, FACP, D-ABOM

02/23/2026

We are still going to aim for 150 minutes a week peeps! But movement in and of itself is medicine!

Can small changes in physical activity make a major difference?

A new meta-analysis suggests that just five extra minutes of moderate physical activity a day is associated with a 10% reduction in all deaths in the majority of adults. Explore the latest data 👉 http://spkl.io/6189AvEML

02/22/2026

Protein isn’t just for gym bros. It’s for protecting muscle while you lose fat.

When you’re in a caloric deficit, your body doesn’t just pull from fat — it can pull from muscle too. Protein is what helps protect lean mass while the scale is moving down.

If you lift: 1.6–2.2 g/kg/day.
If you don’t: 1.2–1.6 g/kg/day.

Women:
90–130 g/day (aim for 30 g with each meal)
110–150 g/day if lifting

Men:
110–150 g/day
140–190 g/day if lifting

And that’s based on ideal or goal body weight — not starting weight if you’re at a higher weight. We don’t calculate protein off excess adipose tissue. We calculate off lean mass goals!

Because fat loss shouldn’t mean muscle loss.
A deficit reduces energy.
Protein preserves structure.

Lose fat.
Keep muscle.
Protect your metabolism.

— Tyler Perrin-Bellelo, MD, FACP, D-ABOM

02/22/2026

The updated NICE 2026 algorithm for managing type two diabetes represents a significant shift from a primarily glucose-centric approach to a more holistic, risk-tailored strategy aimed at reducing cardiovascular and renal complications.

Key points of the new guidance include:

- Most adults with type 2 diabetes should be offered a sodium–glucose co-transporter-2 (SGLT-2) inhibitor alongside metformin as initial therapy. This reflects strong evidence that these agents not only lower blood glucose but also provide heart and kidney protection.
- Access to GLP-1 receptor agonists, such as semaglutide and dulaglutide, as well as the dual agonist tirzepatide, has been expanded. This is particularly beneficial for individuals with established cardiovascular disease, early-onset diabetes, or obesity.

These changes aim to personalize treatment decisions, improve health outcomes, reduce health inequalities, and are projected to prevent thousands of deaths by lowering the risks of end organ damage.

02/21/2026

P*ptide conversation continued.

This isn’t beach weight. It’s about blood sugar, insulin resistance, inflammation, and cardiovascular risk.

Dr. Tyler Perrin-Bellelo, MD, FACP, D-ABOM
Internal Medicine | Obesity Medicine

02/21/2026

This Medical News article discusses the recently released 2025-2030 Dietary Guidelines for Americans.

02/20/2026

We’re watching obesity, cardiometabolic disease, and potentially aging biology itself evolve for the first time ever!

It isn’t whether GLP-1RA’s are here to stay but ensuring that we responsibly integrate them into a long-term healthspan strategy, alongside lifestyle, strength, sleep, and metabolic resilience!

02/19/2026